Dual antiplatelet therapy (DAPT) combines aspirin and a P2Y12 inhibitor. It stops platelets from sticking together, decreasing the risk of blood clots, heart attack and stroke.
You may be prescribed DAPT if you had a heart attack, were treated with stents in your coronary arteries or had coronary artery bypass graft (CABG) surgery. DAPT decreases the risk of future blood clots, heart attack and stroke.
The DAPT Score predicts which patients will benefit from prolonged DAPT after coronary stent placement.
To improve the efficacy over antiplatelet monotherapy, dual antiplatelet therapy (DAPT) has been increasingly adopted in the management of non-cardioembolic stroke.
The benefit of DAPT in patients with NSTE-ACS was first demonstrated in 2001, when the combination of aspirin and clopidogrel reduced cardiovascular events by 20%. 2 Prasugrel and ticagrelor, more potent P2Y 12 receptor inhibitors, are now recommended for most acute coronary syndrome (ACS) patients at lower bleeding risk. 1
Accordingly, the American Heart Association guidelines generally recommend against the use of thrombolytic therapy for patients with minor ischemic strokes or nondisabling symptoms 1 and recommend considering DAPT as an alternative for early initiation of secondary stroke prevention in this population with noncardioembolic AIS. 1 The CHANCE ...
Nanette Kass Wenger, MD, MACC responds: The major academic focus for my decision to recommend extension of dual antiplatelet therapy (DAPT) beyond one year following implantation of a second generation drug eluting stent (DES) derives from the excellent DAPT trial data.
DAPT is also commonly used in the management of ischemic stroke; however, prolonged DAPT therapy does not appear to increase the risk of developing a hemorrhagic stroke.